BLA 022210 · Eurand Pharma LTD
Zenpep
Pancrelipase (Amylase, Lipase, Protease) · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 27, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
n/a
n/a Phase 3, n/a recruiting
FAERS reports
6,026
3,528 serious, 408 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 14, 2025.
ZENPEP ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ZENPEP ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )
Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglycerides, glycerol, and free fatty acids, protein into peptides and amino acids, and starch into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2009 Original approval · Type 7 - Drug Already Marketed without Approved NDA · priority review Summary ReviewPediatric Statistical ReviewPediatric Clinical Pharmacology Review
8 products under this application
- ZENPEP · PANCRELIPASE (AMYLASE 168,000USP UNITS; LIPASE 40,000USP UNITS; PROTEASE) 126,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 14,000USP UNITS; LIPASE 3,000USP UNITS; PROTEASE) 10,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 63,000USP UNITS; LIPASE 15,000USP UNITS; PROTEASE) 47,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 24,000USP UNITS; LIPASE 5,000USP UNITS; PROTEASE) 17,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 252,600USP UNITS; LIPASE 60,000USP UNITS; PROTEASE) 189,600USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 105,000USP UNITS; LIPASE 25,000USP UNITS; PROTEASE) 79,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 84,000USP UNITS; LIPASE 20,000USP UNITS; PROTEASE) 63,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
- ZENPEP · PANCRELIPASE (AMYLASE 42,000USP UNITS; LIPASE 10,000USP UNITS; PROTEASE) 32,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea500
- infective pulmonary exacerbation of cystic fibrosis451
- hospitalisation329
- death296
- cystic fibrosis287
- nausea279
- headache255
- fatigue238
- pneumonia233
- weight decreased222
- drug ineffective209
- abdominal pain205
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 10 |
| 2011 | 10 |
| 2012 | 25 |
| 2013 | 59 |
| 2014 | 100 |
| 2015 | 217 |
| 2016 | 333 |
| 2017 | 337 |
| 2018 | 541 |
| 2019 | 944 |
| 2020 | 778 |
| 2021 | 318 |
| 2022 | 370 |
| 2023 | 562 |
| 2024 | 544 |
| 2025 | 518 |
| 2026 | 360 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zenpep (Lipase/Protease/Amylase)
2024 spending
$597M
Beneficiaries
58,375
259,162 claims
Per beneficiary
$10,234
$11.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $143,420,728 |
| 2022 | $328,785,216 |
| 2023 | $442,806,702 |
| 2024 | $597,436,409 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis.
Taylor CJ, Thieroff-Ekerdt R, Shiff S, et al. · J Cyst Fibros 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis.
Toskes PP, Secci A, Thieroff-Ekerdt R · Pancreas 2011 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review.
Chu P, Mioc J, O'Donovan P, et al. · Digestion 2025 · Systematic Review
- Study of the gastrointestinal bioavailability of a pancreatic extract product (Zenpep) in chronic pancreatitis patients with exocrine pancreatic insufficiency.
Lieb JG, Patel D, Karnik N, et al. · Pancreatology 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
- EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.
Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. · J Cyst Fibros 2009 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Eurand Pharma LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.